Pathogen reduction with methylene blue does not have an impact on the clinical effectiveness of COVID‐19 convalescent plasma

There is a concern about a possible deleterious effect of pathogen reduction (PR) with methylene blue (MB) on the function of immunoglobulins of COVID‐19 convalescent plasma (CCP). We have evaluated whether MB‐treated CCP is associated with a poorer clinical response compared to other inactivation systems at the ConPlas‐19 clinical trial.

[1]  A. Casadevall,et al.  Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma , 2022, Annals of Internal Medicine.

[2]  A. Casadevall,et al.  Pathogen reduction technologies need to evaluate Fc‐mediated antibody functions , 2022, Transfusion.

[3]  A. Casadevall,et al.  COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes , 2022, Clinical microbiology reviews.

[4]  Q. Bassat,et al.  High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial , 2022, The Lancet Respiratory Medicine.

[5]  S. Malnick,et al.  Convalescent Plasma for Outpatients with Covid-19. , 2021, The New England journal of medicine.

[6]  J. Alcamí,et al.  A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. , 2021, The Journal of clinical investigation.

[7]  R. Geller,et al.  Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light. , 2021, Blood transfusion = Trasfusione del sangue.

[8]  A. Gintsburg,et al.  Impact of pathogen reduction methods on immunological properties of the COVID‐19 convalescent plasma , 2021, Vox sanguinis.

[9]  A. Greinacher,et al.  Effect of Methylene Blue Pathogen Inactivation on the Integrity of Immunoglobulin M and G , 2021, Transfusion Medicine and Hemotherapy.

[10]  A. Fernández-Cruz,et al.  Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial , 2020, Trials.

[11]  P. Schlenke.  Pathogen Inactivation Technologies for Cellular Blood Components: an Update , 2014, Transfusion Medicine and Hemotherapy.

[12]  H. Ahsan,et al.  Characterization of Human Serum Immunoglobulin G Modified with Singlet Oxygen , 2013, Indian Journal of Clinical Biochemistry.